Recent Posts
- HealthInvest June 2026: A Look Inside Australia's Healthcare Innovations16 Jun 2026
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences19 May 2026
- Lifesaving Capital: How impact investing is shaping the future of biotech30 Apr 2026
- Investor Relations: the quiet advantage powering ASX microcaps28 Nov 2025
- HealthInvest Sydney: Life Sciences in the Investor Spotlight06 Oct 2025
Archives
Interview with Assoc.Prof. Mathias Francois of Gertrude Biomedical

We talk to Associate Professor Mathias Francois of Gertrude Biomedical, world-leaders in small molecular inhibitors to SOX18, a unique drug target with significant commercial and clinical potential
